SAM
AGRX

Senzar Asset Management’s Agile Therapeutics AGRX Stock Holding History

Senzar Asset Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-181
Closed -$2.75M – 46
2016
Q2 		$2.75M Sell
181
-25
-12% -$342K 0.6% 38
2016
Q1 		$2.56M Buy
206
+13
+7% +$168K 0.51% 34
2015
Q4 		$3.77M Buy
+193
New +$3.05M 0.42% 35

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Senzar Asset Management's AGRX Position: Q3 2016 in Review

Senzar Asset Management sold out of Agile Therapeutics (AGRX) in Q3 2016, closing a stake of 181 shares — an estimated $2.75M sold.

Senzar Asset Management first reported a position in AGRX in Q4 2015 and held it in 3 quarters. The position peaked at $3.77M in Q4 2015. 51 funds tracked by Wall St. Rank hold AGRX as of Q3 2016.

  • Senzar Asset Management reported no remaining Agile Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Senzar Asset Management sold 181 Agile Therapeutics shares in Q3 2016, an estimated $2.75M.
  • Senzar Asset Management first reported a position in Agile Therapeutics in Q4 2015 and held it in 3 quarters.
  • Senzar Asset Management's Agile Therapeutics position peaked at $3.77M in Q4 2015.
  • 51 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2016.

Based on Senzar Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.